Cargando…
A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes
BACKGROUND: Clinical trials are often underpowered to detect serious but rare adverse events of a new medication. We applied a novel data mining tool to detect potential adverse events of canagliflozin, the first sodium glucose co‐transporter 2 (SGLT2 inhibitor) in the United States, using real‐worl...
Autores principales: | Fralick, Michael, Kulldorff, Martin, Redelmeier, Donald, Wang, Shirley V., Vine, Seanna, Schneeweiss, Sebastian, Patorno, Elisabetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279599/ https://www.ncbi.nlm.nih.gov/pubmed/34277962 http://dx.doi.org/10.1002/edm2.237 |
Ejemplares similares
-
UTILIZATION TRENDS OF NEWLY APPROVED GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES
por: Dave, Chintan, et al.
Publicado: (2019) -
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
por: Patorno, Elisabetta, et al.
Publicado: (2019) -
Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States
por: Bykov, Katsiaryna, et al.
Publicado: (2020) -
Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study
por: Fralick, Michael, et al.
Publicado: (2020) -
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments
por: Schneeweiss, Sebastian, et al.
Publicado: (2021)